0.5901 0 (0.02%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 0.84 | 1-year : | 0.95 |
Resists | First : | 0.72 | Second : | 0.81 |
Pivot price | 0.65 ![]() |
|||
Supports | First : | 0.57 | Second : | 0.47 |
MAs | MA(5) : | 0.59 ![]() |
MA(20) : | 0.67 ![]() |
MA(100) : | 0.55 ![]() |
MA(250) : | 1.19 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 10.2 ![]() |
D(3) : | 9 ![]() |
RSI | RSI(14): 39.6 ![]() |
|||
52-week | High : | 2.95 | Low : | 0.34 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CGTX ] has closed above bottom band by 24.0%. Bollinger Bands are 11% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.64 - 0.64 | 0.64 - 0.65 |
Low: | 0.57 - 0.58 | 0.58 - 0.58 |
Close: | 0.58 - 0.59 | 0.59 - 0.6 |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Thu, 30 Jan 2025
CGTX - Cognition Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Wed, 08 Jan 2025
Cognition Therapeutics Advances DLB Treatment After Positive Phase 2 Results, CEO to Present at JPM Week - StockTitan
Wed, 08 Jan 2025
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences - GlobeNewswire
Fri, 20 Dec 2024
B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data - Yahoo Finance
Wed, 18 Dec 2024
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - GlobeNewswire
Thu, 28 Nov 2024
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Nasdaq
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 42 (M) |
Shares Float | 34 (M) |
Held by Insiders | 0.5 (%) |
Held by Institutions | 24.5 (%) |
Shares Short | 816 (K) |
Shares Short P.Month | 531 (K) |
EPS | -0.96 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.75 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -93.7 % |
Return on Equity (ttm) | -108.4 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.42 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -23 (M) |
Levered Free Cash Flow | -30 (M) |
PE Ratio | -0.62 |
PEG Ratio | 0 |
Price to Book value | 0.77 |
Price to Sales | 0 |
Price to Cash Flow | -1.08 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |